Physician profile
Daniel A Ng
NPI 1265523351
$10,189.45
in general payments reported to CMS, 2019-2025
14 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,219 · 2020: $962 · 2021: $14.90 · 2022: $159 · 2023: $543 · 2024: $140 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434 · Gift: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.06 |
| Gift | $400.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,973.00 | 2019-2023 | |
| Braintree Laboratories, INC. | $689.51 | 2019-2024 | Sutab, Suflave |
| Davol INC. | $97.63 | 2019-2023 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $91.78 | 2020-2025 | |
| Lilly USA, LLC | $88.71 | 2024-2025 | Omvoh |
| Genzyme Corporation | $55.62 | 2023 | |
| Madrigal Pharmaceuticals | $43.15 | 2025 | Rezdiffra |
| Covidien LP | $39.60 | 2019 | |
| Vioptix INC | $24.61 | 2023 | |
| Ferring Pharmaceuticals INC. | $23.59 | 2023 | Rebyota |
| Shire North American Group INC | $19.17 | 2019 | |
| Janssen Biotech, INC. | $16.57 | 2023 | Stelara |
| Convatec INC. | $15.91 | 2019 | |
| Vivus LLC | $10.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.